Levothyroxine treatment in euthyroid women positive for thyroid peroxidase antibodies and recurrent pregnancy loss
- PMID: 35298918
- DOI: 10.1016/S2213-8587(22)00079-1
Levothyroxine treatment in euthyroid women positive for thyroid peroxidase antibodies and recurrent pregnancy loss
Conflict of interest statement
TIMK reports lecture fees from Berlin-Chemie, Goodlife Healthcare, EXCEMED, Merck, IBSA, and Quidel, and currently serves as the co-chair of the 2023 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Preconception, Pregnancy and the Postpartum guideline committee. RD-S serves as the Fertility and Assisted Reproduction working group coordinator of the 2023 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Preconception, Pregnancy and the Postpartum guideline committee.
Comment on
-
Levothyroxine in euthyroid thyroid peroxidase antibody positive women with recurrent pregnancy loss (T4LIFE trial): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Diabetes Endocrinol. 2022 May;10(5):322-329. doi: 10.1016/S2213-8587(22)00045-6. Epub 2022 Mar 14. Lancet Diabetes Endocrinol. 2022. PMID: 35298917 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources